Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (1819)	1/17/1998 1:52:00 AM
From: Bill Wexler	Read Replies (1) \| Respond to of 7041

Here is what we know so far: 1) Zonagen has a history of filing tainted paperwork. It is already estblished that they tried submitting a patent application for Immumax when they knew that a prior patent existed for Chitosan. The patent was - of course - rejected. Zonagen still tried to push Immumax on to Scering-Plough, but had to back out of the deal when the patent was denied. Schering-Plough did not know that Podolski and the officers already knew that they were trying to pull a fast one, fortunately we have a disgruntled ex-director of immunology to shed a little light as to what went on behind the scenes. 2) Zonagen's patent for Vasomax will be denied. There can be no doubt about this. An examination of the international patent application clearly demonstrates that the Vasomax formulation is not unique. 3) I think that Schering will have to shepherd the NDA. However; I am inclined to think (after a few lengthy phone calls to my contacts) that no NDA will be filed unless the patent app is approved. Zonagen has put itself in a double bind by diverting attention away from the generic phentolamine and touting the "unique" oral formulation. 4) The FDA has already kicked Vasomax back for "more testing". I believe that there is slim to no chance that an NDA will be filed; and slim is out of town.